Summary: Dapagliflozin is an SGLT-2 Inhibitor that reduces blood sugar by increasing the excretion of sugar through the urine. <br> <br> <br> <br> Genital and urinary infections is a potential risk with the use of SGLT2 Inhibitors like dapagliflozin.<br> <br> <br> <br> Dapagliflozin has received FDA approval for use in heart failure (in patients even without diabetes). <br> <br> <br> <br> Be aware of agents that may enhance the risk for hypoglycemia such an insulin and sulfonylureas.
